The approval of Lenacapavir – a twice-yearly antiviral HIV-preventing medication marketed under the brand name Yeztugo – by the US Food and Drug Administration (FDA), has been welcomed by the global ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...

WASHINGTON -- The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It's the first step in an anticipated global rollout that could ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk […] The ...

WASHINGTON (AP) — The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences ... better than daily preventive pills they can forget to take.

which is usually taken as daily pills. PrEP and now lenacapavir have come along during a momentous progression in the prevention and treatment of HIV in recent decades. A crucial breakthrough has ...